Sequencing Options of Bispecifics in R/R MM
Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.
Video Player is loading.
EP: 1.Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma
EP: 2.Treatment Options in Late-line R/R MM Patients
Now Viewing
EP: 3.Sequencing Options of Bispecifics in R/R MM
EP: 4.Pooled Analysis from MagnetisMM Studies
EP: 5.Consideration in Treatment Selection and Sequencing in R/R MM
EP: 6.Clinical Scenario 2: A 70-Year-Old Male with R/R MM
EP: 7.Treatment Options for Late-line R/R MM
EP: 8.Overview of CAR-T Sequencing Strategies in R/R MM
EP: 9.Challenges in Optimizing Sequencing
EP: 10.Future Clinical Trials: Sequencing Decisions for Bispecifics and CAR T-Cell Therapy
EP: 11.Challenges in Optimizing Sequencing Strategies in R/R MM
EP: 12.Unmet Needs and Future Perspectives in Treatment Sequencing Strategies in R/R MM
Recent Videos
Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Research Considerations for ctDNA Testing in Colorectal Cancer
Expert Perspectives: Tazemetostat in R/R FL
The Role of ctDNA Testing in Colorectal Cancer Management: Exploring Its Use Alongside Imaging in Challenging Cases
Related Content
